Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 02 - 17 tags : Cancer save search
VIDEO: Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Published: 2022-02-17 (Crawled : 22:00) - poseida.com
PSTX | News | $2.0 -1.96% -1.75% 0
|
Health Technology
|
| O: 0.0%
H: 0.95%
C: -15.2%
psma-101 prostate cancer state car-t cel phase 1 cancer phase 2 t-cell
Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Published: 2022-02-17 (Crawled : 20:00) - poseida.com
PSTX | News | $2.0 -1.96% -1.75% 0
|
Health Technology
|
| O: -2.24%
H: 15.34%
C: 12.61%
psma-101 prostate cancer state car-t cel phase 1 cancer phase 2 t-cell
APDN, EvviVax Announce Publication of Positive Preclinical Data for Linear DNA™ Platform Approach to Cancer Immunotherapy
Published: 2022-02-17 (Crawled : 17:00) - adnas.com
APDN | $0.3376 1.38% 3.79% 0
|
Commercial Services
|
| O: -1.01%
H: 2.03%
C: -3.05%
preclinical immunotherapy positive therapy cancer platform pre-clinical
Applied DNA and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
APDN | $0.3376 1.38% 3.79% 0
|
Commercial Services
|
| O: -1.01%
H: 2.03%
C: -3.05%
preclinical immunotherapy positive therapy cancer platform pre-clinical
Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
ALKS | $23.64 -0.51% 50K
|
Health Technology
|
| O: -1.19%
H: 1.13%
C: -4.23%
america symposium nemvaleukin therapy cancer
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
LLY | $745.95 -0.64% -0.13% 17K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.88%
VERU | $1.42 22.41% 12.12% 68K
|
Health Technology
|
| O: -0.96%
H: 0.88%
C: -3.38%
prostate cancer symposium state phase 1b presentation asco phase 1 cancer sabizabulin phase 2b
Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
ARVN | $34.29 12K
|
Health Technology
|
| O: -0.53%
H: 0.96%
C: -3.06%
arv-110 protac prostate cancer state cancer
Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium
Published: 2022-02-17 (Crawled : 14:00) - biospace.com/
PSTX | News | $2.0 -1.96% -1.75% 0
|
Health Technology
|
| O: 0.0%
H: 0.95%
C: -15.2%
psma-101 symposium trial therapeutics asco phase 1 results cancer phase 2
Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress
Published: 2022-02-17 (Crawled : 13:00) - prnewswire.com
ENVB | $0.938 2.2K
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: -6.6%
evm-101 trial bioscience cancer
Brain Tumor Diagnostics Market- 43% of the market's growth from North America| Increasing Prevalence of Cancer to Boost Market Growth|17000+ Technavio Research Reports
Published: 2022-02-17 (Crawled : 11:00) - prnewswire.com
RYLPF | News | $20.515 3.85% 7K
|
Health Technology
|
| O: -0.72%
H: 0.93%
C: 0.57%
TMO | News | $541.52 -1.05% 0.0% 5.4K
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: -1.86%
diagnostic america research diagnostics report cancer growth market train
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | News | $1.4 250.0% 35M
|
Finance
RWOD | $12.0 50.06% 3.9M
|
n/a
INDO | $4.9 20.1% 2.2M
|
Energy Minerals
NURO | $4.32 18.36% 66K
|
Health Technology
HUBC | $1.52 17.83% 4.7M
|
n/a
CARV 4 | $1.77 11.32% 8.5K
|
Finance
BROG | $1.23 10.81% 320K
|
Finance
PARA | $12.03 9.66% 5.8M
|
Information
ADAP | $0.98 9.08% 240K
|
Health Technology
POAI A | $1.25 8.69% 16K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.